A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Who May Qualify: - Have been diagnosed with plaque psoriasis by a dermatologist - Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) - Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Who Should NOT Join This Trial: - Participation (current or planned) in an interventional clinical trial (does not include observational registry or study) - Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history Always talk to your doctor about whether this trial is right for you.